Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment

By MarketWatch   |   1 year ago
Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment

Rezolute has been granted an orphan-drug designation by the FDA for its hypoglycemia treatment caused by insulin-producing tumors. The treatment, ersodetug, is set to begin Phase 3 trials in 2025 for tumor hyperinsulinism.

Read More

Did you find this insightful?